Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Purchases $17,200.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of Anixa Biosciences stock in a transaction that occurred on Monday, July 27th. The shares were acquired at an average price of $3.44 per share, with a total value of $17,200.00. Following the acquisition, the chief executive officer directly owned 652,000 shares of the company’s stock, valued at $2,242,880. The trade was a 0.77% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.04 per share, with a total value of $15,200.00.
• On Friday, June 12th, Amit Kumar acquired 21,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $3.56 on Friday. The stock has a market capitalization of $121.12 million, a price-to-earnings ratio of -11.48 and a beta of 0.59. The business has a 50-day moving average of $2.96 and a 200-day moving average of $2.92. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. On average, sell-side analysts expect that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds have recently bought and sold shares of ANIX. NewEdge Advisors LLC bought a new position in Anixa Biosciences during the second quarter worth about $33,000. Northwestern Mutual Wealth Management Co. raised its stake in Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after buying an additional 10,000 shares during the period. Cetera Investment Advisers bought a new stake in Anixa Biosciences in the fourth quarter valued at approximately $35,000. Benjamin Edwards Inc. bought a new stake in Anixa Biosciences in the second quarter valued at approximately $37,000. Finally, Marshall Wace LLP acquired a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $39,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on ANIX. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Finally, Zacks Research upgraded shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.